Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04865315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

Study acronym: HiLoGlio
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Active, Not Recruiting to Recruiting Primary and study completion dates: Dec 2024 to Dec 2028 · Site details revisedv4 Show 2 more changesShow less
    • Primary and study completion dates: Dec 2024 to Dec 2028
    • Site details revised
  3. Re-verified, no change to tracked fieldsv3
  4. Start date: Feb 1, 2021 to May 1, 2022v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.
Trial Details
NCT Number NCT04865315
Lead Sponsor Maastricht Radiation Oncology
Collaborators: Maastricht University Medical Center, Zuyderland Medisch Centrum, Ziekenhuis Oost-Limburg
Conditions Low-grade Glioma, High Grade Glioma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov